-+ 0.00%
-+ 0.00%
-+ 0.00%

CARsgen says satri-cel gastric cancer consolidation trial shows no recurrences to date

PUBT·07/15/2026 00:00:39
Listen to the news
CARsgen says satri-cel gastric cancer consolidation trial shows no recurrences to date
  • CARsgen disclosed preliminary positive results for satri-cel as consolidation therapy in resected gastric or gastroesophageal junction cancer.
  • An abstract from the China IIT trial CT041-CG4010 (NCT06857786) was accepted for poster presentation at ESMO Congress 2026.
  • Since enrollment began in May 2025, no satri-cel-treated participants have reported postoperative recurrence or metastasis, as of the announcement date.
  • The ESMO abstract is scheduled for online publication at 00:05 CEST on Oct. 19, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260715-12244476), on July 15, 2026, and is solely responsible for the information contained therein.